Friday 6 November 2026 Export JNJ’s income statement to Excel — free account

Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.

Revenue: +5.86%
EPS: −95.8%
Free cash flow: −21.4%
Total debt: −9.16%

Quarter to September 2026, against a year earlier

272.44 3.88 −1.40%

Follow JNJ

Alert me

Market cap: $655.6B
P/E: 41.3×
Fwd P/E: 40.0×
Dividend yield: 1.94%
F-score: 3/9
Altman Z: 4.78
Beneish M: −2.26
Dividend safety: 78/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Johnson & Johnson (JNJ) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Johnson & Johnson (JNJ) trades at a price to free cash flow of 31.3×. Over the past ten years it has ranged from 12.7× (March 2020) to 34.1× (June 2026); the current reading is higher than 99% of that period. That is above the Drug Manufacturers General industry median of 21.3× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/JNJ/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Johnson &amp; Johnson price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/JNJ/metrics/price-to-free-cash-flow">Johnson &amp; Johnson (JNJ) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	24.4×	43.80%
FY2024	17.0×	(22.10%)
FY2023	21.8×	(17.45%)
FY2022	26.4×	19.95%
FY2021	22.0×	8.80%
FY2020	20.2×	21.48%
FY2019	16.6×	4.53%
FY2018	15.9×	(16.70%)
FY2017	19.1×	1.32%
FY2016	18.9×	29.67%

Period	Price to free cash flow	Change
Sep 2026	30.4×	12.96%
Jun 2026	26.9×	(16.58%)
Mar 2026	32.3×	32.19%
Dec 2025	24.4×	9.60%
43 more quarters	Free account

Against its own ten years

Low 12.7× High 34.1×

Ten-year median 19.1×

Current reading's percentile 99

Company	Price to free cash flow
GILD Gilead Sciences, Inc. compare	15.1×
PFE Pfizer Inc. compare	15.5×
NVS Novartis AG compare	21.7×
MRK Merck & Co., Inc. compare	22.6×
ABBV AbbVie Inc. compare	27.1×
AMGN Amgen Inc. compare	27.3×
JNJ Johnson & Johnson	31.3×
AZN AstraZeneca PLC compare	45.8×
LLY Eli Lilly and Company compare	55.9×
Drug Manufacturers General industry median	21.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Johnson & Johnson (JNJ) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on JNJ

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on JNJ

Stockrow Weekly